Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies

Epigenetic mechanisms such as DNA methylation and modifications to histone proteins regulate high-order DNA structure and gene expression. Aberrant epigenetic mechanisms are involved in the development of many diseases, including cancer. The neurological disorder most intensely studied with regard to epigenetic changes is Rett syndrome; patients with Rett syndrome have neurodevelopmental defects associated with mutations in MeCP2, which encodes the methyl CpG binding protein 2, that binds to methylated DNA. Other mental retardation disorders are also linked to the disruption of genes involved in epigenetic mechanisms; such disorders include alpha thalassaemia/mental retardation X-linked syndrome, Rubinstein-Taybi syndrome, and Coffin-Lowry syndrome. Moreover, aberrant DNA methylation and histone modification profiles of discrete DNA sequences, and those at a genome-wide level, have just begun to be described for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and in other neurological disorders such as multiple sclerosis, epilepsy, and amyotrophic lateral sclerosis. In this Review, we describe epigenetic changes present in neurological diseases and discuss the therapeutic potential of epigenetic drugs, such as histone deacetylase inhibitors.

[1]  S. Haggarty,et al.  HDAC2 negatively regulates memory formation and synaptic plasticity , 2009, Nature.

[2]  Kristian Helin,et al.  The emerging functions of histone demethylases. , 2008, Current opinion in genetics & development.

[3]  J L Haines,et al.  Supporting Online Material Materials and Methods Figs. S1 to S7 Tables S1 to S4 References Mutations in the Fus/tls Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis , 2022 .

[4]  M. Druse,et al.  S100B-mediated protection against the pro-apoptotic effects of ethanol on fetal rhombencephalic neurons , 2007, Brain Research.

[5]  R. Ophoff,et al.  Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration , 2008, Human molecular genetics.

[6]  D. Higgs,et al.  Loss of Atrx Affects Trophoblast Development and the Pattern of X-Inactivation in Extraembryonic Tissues , 2006, PLoS genetics.

[7]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[8]  A. Hanauer,et al.  Coffin-Lowry syndrome: clinical and molecular features , 2002, Journal of medical genetics.

[9]  C. Polman,et al.  Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis , 2009, The Lancet Neurology.

[10]  Robert H. Brown,et al.  Amyotrophic Lateral Sclerosis-Associated SOD1 Mutant Proteins Bind and Aggregate with Bcl-2 in Spinal Cord Mitochondria , 2004, Neuron.

[11]  K. Kyvik,et al.  Concordance for multiple sclerosis in Danish twins: an update of a nationwide study , 2005, Multiple sclerosis.

[12]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[13]  I. Verma,et al.  Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. , 2008, The American journal of pathology.

[14]  Xiuli Wang,et al.  Gcn5- and Elp3-induced histone H3 acetylation regulates hsp70 gene transcription in yeast. , 2008, The Biochemical journal.

[15]  P. Wade,et al.  MBD family proteins: reading the epigenetic code , 2006, Journal of Cell Science.

[16]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[17]  R. Dingledine,et al.  Altered Histone Acetylation at Glutamate Receptor 2 and Brain-Derived Neurotrophic Factor Genes Is an Early Event Triggered by Status Epilepticus , 2002, The Journal of Neuroscience.

[18]  T. Kouzarides Chromatin Modifications and Their Function , 2007, Cell.

[19]  N. Belyaev,et al.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease , 2009, EMBO reports.

[20]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[21]  T. Bruxner,et al.  A genome-wide screen for modifiers of transgene variegation identifies genes with critical roles in development , 2008, Genome Biology.

[22]  I. Krantz,et al.  Mutations in the chromatin‐associated protein ATRX , 2008, Human mutation.

[23]  E. Schorry,et al.  Genotype–phenotype correlations in Rubinstein–Taybi syndrome , 2008, American journal of medical genetics. Part A.

[24]  R. Wells,et al.  Long intronic GAA•TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia , 2008, Nucleic acids research.

[25]  M. Fraga,et al.  Histone H3 and H4 Modification Profiles in a Rett Syndrome Mouse Model , 2007, Epigenetics.

[26]  J. Sng,et al.  Histone modifications in kainate‐induced status epilepticus , 2006, The European journal of neuroscience.

[27]  Monika S. Kowalczyk,et al.  Structural consequences of disease-causing mutations in the ATRX-DNMT3-DNMT3L (ADD) domain of the chromatin-associated protein ATRX , 2007, Proceedings of the National Academy of Sciences.

[28]  S. Sakoda,et al.  Benefit of valproic acid in suppressing disease progression of ALS model mice , 2004, The European journal of neuroscience.

[29]  K. Kyvik,et al.  Risk for multiple sclerosis in dizygotic and monozygotic twins , 2005, Multiple sclerosis.

[30]  D. Chuang,et al.  Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model , 2008, Neuroscience.

[31]  M. Esteller,et al.  Mecp2-Null Mice Provide New Neuronal Targets for Rett Syndrome , 2008, PloS one.

[32]  A. Pombo,et al.  Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. Jeanmougin,et al.  A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. , 1996, The EMBO journal.

[34]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[35]  W. Reik,et al.  Epigenetic Reprogramming in Mammalian Development , 2001, Science.

[36]  M. Esteller Epigenetics in evolution and disease , 2008, The Lancet.

[37]  R. Hennekam Rubinstein–Taybi syndrome , 2005, European Journal of Human Genetics.

[38]  F. Mastronardi,et al.  Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: A contribution to the current debate on disease pathogenesis , 2008, Progress in Neurobiology.

[39]  A. Minagar,et al.  HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. , 2007, International review of neurobiology.

[40]  A. Wilkie,et al.  X-linked alpha-thalassemia/mental retardation (ATR-X) syndrome: localization to Xq12-q21.31 by X inactivation and linkage analysis. , 1992, American journal of human genetics.

[41]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[42]  Yong-Yeon Cho,et al.  The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. , 2005, Cancer research.

[43]  H. Schaeffer,et al.  Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers , 1999, Molecular and Cellular Biology.

[44]  P. Mcgeer,et al.  Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide , 2001, Neuroscience Letters.

[45]  G. Mandel,et al.  Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology , 2009, Nature Neuroscience.

[46]  N. Risch,et al.  Twin concordance and sibling recurrence rates in multiple sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. Sassone-Corsi,et al.  Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Fraga,et al.  The impact of MECP2 mutations in the expression patterns of Rett syndrome patients , 2004, Human Genetics.

[49]  D. Higgs,et al.  Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation , 2000, Nature Genetics.

[50]  C. Glass,et al.  Induced ncRNAs Allosterically Modify RNA Binding Proteins in cis to Inhibit Transcription , 2008, Nature.

[51]  Sun-Chong Wang,et al.  Age-Specific Epigenetic Drift in Late-Onset Alzheimer's Disease , 2008, PloS one.

[52]  Huda Y. Zoghbi,et al.  The Story of Rett Syndrome: From Clinic to Neurobiology , 2007, Neuron.

[53]  N. Landsberger,et al.  CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. , 2005, Human molecular genetics.

[54]  A. Nordberg,et al.  Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with Aβ levels , 2008, Neurobiology of Aging.

[55]  G. Brady,et al.  The role of charge microheterogeneity of basic protein in the formation and maintenance of the multilayered structure of myelin: A possible role in multiple sclerosis , 1986, Journal of neuroscience research.

[56]  M. Esteller Relevance of DNA methylation in the management of cancer. , 2003, The Lancet. Oncology.

[57]  N. Youngson,et al.  Transgenerational epigenetic effects. , 2008, Annual review of genomics and human genetics.

[58]  M. Stratton,et al.  Mutations in the RSK2(RPS6KA3) gene cause Coffin–Lowry syndrome and nonsyndromic X‐linked mental retardation , 2006, Clinical genetics.

[59]  M. Esteller Rett Syndrome: The First Forty Years 1966-2006 , 2007, Epigenetics.

[60]  B. Weinshenker,et al.  Men transmit MS more often to their children vs women , 2006, Neurology.

[61]  C. Allis,et al.  PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. , 2008, Mutation research.

[62]  T. Spector,et al.  Epigenetic differences arise during the lifetime of monozygotic twins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[63]  M. Gunzburg,et al.  Structural Basis for the Recognition and Cross-linking of Amyloid Fibrils by Human Apolipoprotein E* , 2007, Journal of Biological Chemistry.

[64]  Kunlin Chen,et al.  The epigenetic effects of amyloid-beta(1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. , 2009, Biochemical and biophysical research communications.

[65]  Shiu-Hwa Yeh,et al.  Acetylation of nuclear factor-kappaB in rat amygdala improves long-term but not short-term retention of fear memory. , 2004, Molecular pharmacology.

[66]  S. Hersch,et al.  Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. , 2007, Human molecular genetics.

[67]  Y. Suh,et al.  Inhibition of histone deacetylation enhances the neurotoxicity induced by the c‐terminal fragments of amyloid precursor protein , 2004, Journal of neuroscience research.

[68]  I. Takasaki,et al.  Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions , 2009, Neuroscience Research.

[69]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[70]  Fabrice P Cordelières,et al.  Histone Deacetylase 6 Inhibition Compensates for the Transport Deficit in Huntington's Disease by Increasing Tubulin Acetylation , 2007, The Journal of Neuroscience.

[71]  D. Schoenfeld,et al.  Phase 2 study of sodium phenylbutyrate in ALS , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[72]  G. Harauz,et al.  Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[73]  D. Higgs,et al.  Mutations in a putative global transcriptional regulator cause X-linked mental retardation with α-thalassemia (ATR-X syndrome) , 1995, Cell.

[74]  Y. Jong,et al.  Treatment of spinal muscular atrophy by sodium butyrate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[76]  Y. Itoyama,et al.  Alteration of familial ALS-linked mutant SOD1 solubility with disease progression: its modulation by the proteasome and Hsp70. , 2006, Biochemical and biophysical research communications.

[77]  A. Bird,et al.  Reversal of Neurological Defects in a Mouse Model of Rett Syndrome , 2007, Science.

[78]  A. Feinberg Phenotypic plasticity and the epigenetics of human disease , 2007, Nature.

[79]  R. Holliday DNA methylation and epigenetic defects in carcinogenesis. , 1987, Mutation research.

[80]  B. Oostra,et al.  In vitro reactivation of the FMR1 gene involved in fragile X syndrome. , 1998, Human molecular genetics.

[81]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[82]  Y. She,et al.  Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry. , 2005, Biochemistry.

[83]  M. Mayford,et al.  CBP Histone Acetyltransferase Activity Is a Critical Component of Memory Consolidation , 2004, Neuron.

[84]  R. Jaenisch,et al.  Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Jonathan Pevsner,et al.  DNA methylation signatures within the human brain. , 2007, American journal of human genetics.

[86]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[87]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[88]  R. Jaenisch,et al.  Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice , 2001, Nature Genetics.

[89]  Samuel F. Berkovic,et al.  Mechanisms of human inherited epilepsies , 2009, Progress in Neurobiology.

[90]  J. Gécz,et al.  Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. , 2004, American journal of human genetics.

[91]  G. Carraz,et al.  [Pharmacodynamic properties of N-dipropylacetic acid]. , 1963, Therapie.

[92]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[93]  R. Gibbons Alpha thalassaemia-mental retardation, X linked , 2006, Orphanet journal of rare diseases.

[94]  M. Mehler Epigenetic principles and mechanisms underlying nervous system functions in health and disease , 2008, Progress in Neurobiology.

[95]  H. Zoghbi,et al.  Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. , 2004, Human molecular genetics.

[96]  T. Russo,et al.  Fe65 is required for Tip60-directed histone H4 acetylation at DNA strand breaks , 2009, Proceedings of the National Academy of Sciences.

[97]  R. Bourtchouladze,et al.  Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction , 2006, Cellular and Molecular Life Sciences.

[98]  J A Eisen,et al.  Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. , 1995, Nucleic acids research.

[99]  Christopher K. Glass,et al.  Exchange of N-CoR Corepressor and Tip60 Coactivator Complexes Links Gene Expression by NF-κB and β-Amyloid Precursor Protein , 2002, Cell.

[100]  J. Qin,et al.  The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Ankita Patel,et al.  Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males , 2006, Genetics in Medicine.

[102]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[103]  Pascal G. P. Martin,et al.  Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator , 2005, The Journal of cell biology.

[104]  F. Gao Posttranscriptional control of neuronal development by microRNA networks , 2008, Trends in Neurosciences.

[105]  R. Ferrante,et al.  Modulation of nucleosome dynamics in Huntington's disease. , 2007, Human molecular genetics.

[106]  T. Deguchi,et al.  Phosphorylation by extracellular signal‐regulated kinase of a multidomain adaptor protein, vinexin, at synapses , 2007, Journal of neurochemistry.

[107]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[108]  R. Jaenisch,et al.  DNA Methylation in the Human Cerebral Cortex Is Dynamically Regulated throughout the Life Span and Involves Differentiated Neurons , 2007, PloS one.

[109]  Miguel Alaminos,et al.  A microarray-based DNA methylation study of glioblastoma multiforme , 2009, Epigenetics.

[110]  E. Kalkhoven,et al.  CBP and p300: HATs for different occasions. , 2004, Biochemical pharmacology.

[111]  E. Lander,et al.  The Mammalian Epigenome , 2007, Cell.

[112]  S. Timsit,et al.  Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. , 1998, Human molecular genetics.

[113]  E. Zackai,et al.  Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome , 1996, Nature.

[114]  Hyoung-Gon Lee,et al.  Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes , 2008, AGE.

[115]  Marcelo A Wood,et al.  Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. , 2005, Learning & memory.

[116]  J H RUBINSTEIN,et al.  Broad thumbs and toes and facial abnormalities. A possible mental retardation syndrome. , 1963, American journal of diseases of children.

[117]  D. Harvey,et al.  Rett Syndrome Astrocytes Are Abnormal and Spread MeCP2 Deficiency through Gap Junctions , 2009, The Journal of Neuroscience.

[118]  P. Riederer,et al.  Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability , 2008, Neurobiology of Disease.

[119]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[120]  J. Clayton-Smith,et al.  Clinical and hematologic aspects of the X-linked α-thalassemia/mental retardation syndrome (ATR-X) , 1995 .

[121]  R. Ferrante,et al.  ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease , 2006, Proceedings of the National Academy of Sciences.

[122]  J. Parvin,et al.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.

[123]  C. Poser The multiple sclerosis trait and the development of multiple sclerosis: Genetic vulnerability and environmental effect , 2006, Clinical Neurology and Neurosurgery.

[124]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[125]  Joel M Stein,et al.  Histone Deacetylase Inhibitors Enhance Memory and Synaptic Plasticity via CREB: CBP-Dependent Transcriptional Activation , 2007, The Journal of Neuroscience.

[126]  Jan Hillert,et al.  HLA-A Confers an HLA-DRB1 Independent Influence on the Risk of Multiple Sclerosis , 2007, PloS one.

[127]  N. Bérubé,et al.  Cell cycle-dependent phosphorylation of the ATRX protein correlates with changes in nuclear matrix and chromatin association. , 2000, Human molecular genetics.

[128]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[129]  I. Young,et al.  The Coffin-Lowry syndrome. , 1988, Journal of medical genetics.

[130]  M. Bieda,et al.  Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes , 2007, Proceedings of the National Academy of Sciences.

[131]  K. Wigglesworth,et al.  ATRX, a member of the SNF2 family of helicase/ATPases, is required for chromosome alignment and meiotic spindle organization in metaphase II stage mouse oocytes. , 2004, Developmental biology.

[132]  A. Bird DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[133]  S. Perlman,et al.  Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia , 2006, Nature chemical biology.

[134]  G. Stephanopoulos,et al.  Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis , 2005, Journal of Neuroimmunology.

[135]  A. Sadovnick,et al.  Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. , 2008, Human molecular genetics.

[136]  E. Nestler,et al.  Histone Modifications at Gene Promoter Regions in Rat Hippocampus after Acute and Chronic Electroconvulsive Seizures , 2004, The Journal of Neuroscience.

[137]  S. Koschmieder,et al.  S100A2 Induces Metastasis in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[138]  M. Esteller Epigenetics in cancer. , 2008, The New England journal of medicine.

[139]  Andrew L Kung,et al.  Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. , 2008, Human molecular genetics.

[140]  A. Harel-Bellan,et al.  Mitogen-Regulated RSK2-CBP Interaction Controls Their Kinase and Acetylase Activities , 2001, Molecular and Cellular Biology.

[141]  T. Saido,et al.  Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.

[142]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[143]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[144]  M. Esteller,et al.  Proteins that bind methylated DNA and human cancer: reading the wrong words , 2008, British Journal of Cancer.

[145]  C. Ackerley,et al.  Myelin in multiple sclerosis is developmentally immature. , 1994, The Journal of clinical investigation.

[146]  D. Krainc,et al.  Sodium phenylbutyrate in Huntington's disease: A dose‐finding study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[147]  Masatoshi Hagiwara,et al.  Phosphorylated CREB binds specifically to the nuclear protein CBP , 1993, Nature.

[148]  J. De Belleroche,et al.  Hsp27 and Hsp70 administered in combination have a potent protective effect against FALS-associated SOD1-mutant-induced cell death in mammalian neuronal cells. , 2005, Brain research. Molecular brain research.

[149]  W. Gerald,et al.  Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. , 2004, Journal of the National Cancer Institute.

[150]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[151]  A. Noor,et al.  Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated , 2007, Journal of neuroscience research.

[152]  M. Esteller Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[153]  M. Paz,et al.  CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas , 2004, Clinical Cancer Research.

[154]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[155]  R. Hennekam,et al.  Growth in the Rubinstein-Taybi syndrome. , 2005, American journal of medical genetics. Supplement.

[156]  F. Mastronardi,et al.  The Role of Citrullinated Proteins Suggests a Novel Mechanism in the Pathogenesis of Multiple Sclerosis , 2006, Neurochemical Research.

[157]  John Peterson Myers,et al.  Environmental Exposures and Gene Regulation in Disease Etiology , 2007, Environmental health perspectives.

[158]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[159]  D. Geschwind,et al.  HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model , 2008, PloS one.

[160]  J. Gécz,et al.  Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. , 2004, American journal of human genetics.

[161]  J. Haines,et al.  Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. , 1998, Human molecular genetics.

[162]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[163]  A. Bird,et al.  Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation , 2007, Proceedings of the National Academy of Sciences.

[164]  E. Seemanová,et al.  DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein–Taybi syndrome (RSTS) and in another patient with incomplete RSTS , 2005, Human Genetics.

[165]  H. Harbo,et al.  Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis , 2007, Nature Genetics.

[166]  Li-Huei Tsai,et al.  Recovery of learning and memory is associated with chromatin remodelling , 2007, Nature.

[167]  R. Touraine,et al.  A syndromic form of X-linked mental retardation: the Coffin-Lowry syndrome , 2002, European Journal of Pediatrics.

[168]  F. Dick,et al.  Loss of ATRX leads to chromosome cohesion and congression defects , 2008, The Journal of cell biology.

[169]  A. Cantani,et al.  Rubinstein-Taybi syndrome. Review of 732 cases and analysis of the typical traits. , 1998, European review for medical and pharmacological sciences.

[170]  Stephen L. Hauser,et al.  The genetics of multiple sclerosis: SNPs to pathways to pathogenesis , 2008, Nature Reviews Genetics.

[171]  M. Beal,et al.  Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease* , 2005, Journal of Biological Chemistry.

[172]  E. Bézard,et al.  Striatal histone modifications in models of levodopa‐induced dyskinesia , 2008, Journal of neurochemistry.

[173]  D. Trabzuni,et al.  The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. , 2007, Human molecular genetics.

[174]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[175]  B. Wirth,et al.  Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition , 2008, Human molecular genetics.

[176]  Nathan R. Wilson,et al.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice , 2009, Proceedings of the National Academy of Sciences.

[177]  D. Molfese,et al.  Regulation of Histone Acetylation during Memory Formation in the Hippocampus* , 2004, Journal of Biological Chemistry.

[178]  M. Z. Cader,et al.  Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. , 2005, Human molecular genetics.

[179]  Johan T den Dunnen,et al.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. , 2005, American journal of human genetics.

[180]  R. D. L. Fuente,et al.  ATRX marks the inactive X chromosome (Xi) in somatic cells and during imprinted X chromosome inactivation in trophoblast stem cells , 2009, Chromosoma.

[181]  E. Kandel,et al.  Chromatin Acetylation, Memory, and LTP Are Impaired in CBP+/− Mice A Model for the Cognitive Deficit in Rubinstein-Taybi Syndrome and Its Amelioration , 2004, Neuron.

[182]  M. J. Barratt,et al.  Phosphoacetylation of histone H3 on c‐fos‐ and c‐jun‐associated nucleosomes upon gene activation , 2000, The EMBO journal.

[183]  A. Ferguson-Smith,et al.  Mechanisms regulating imprinted genes in clusters. , 2007, Current opinion in cell biology.

[184]  Manel Esteller,et al.  Towards the Human Cancer Epigenome: A First Draft of Histone Modifications , 2005, Cell cycle.